BridgeBio Pharma, Inc. — Director's Dealing 2020

Feb 14, 2020

SEC Form 5/A — Form 5/A

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2019-12-31

Reporting Person: Kumar Neil (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-30	Common Stock	G	400375	$0.00	Disposed	0	Indirect
2019-12-30	Common Stock	G	66730	$0.00	Acquired	4685725	Direct

Footnotes

F1: The shares were originally held by Neil Kumar LLC, of which the Reporting Person shared voting, investment and dispositive power with the other LLC member. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares were beneficially owned by the Reporting Person for Section 16 or any other purposes.